Search

Your search keyword '"Bizhan Bandarchi-Chamkhaleh"' showing total 2 results
Start Over Author "Bizhan Bandarchi-Chamkhaleh" Search Limiters Peer Reviewed
2 results on '"Bizhan Bandarchi-Chamkhaleh"'

1. Correlation of Minichromosome Maintenance Protein 6 Expression Rate and Clinical Outcome in Patients With Hodgkin's Lymphoma

Author

Kian Khodadad, Shirin Karimi, Zahra Esfahani-Monfared, Adnan Khosravi, and Bizhan Bandarchi-Chamkhaleh

Subjects
Hodgkin’s disease, Minichromosome maintenance complex component 6 (MCM-6), Lymphoma, Medicine (General), R5-920
Abstract

Minichromosome maintenance complex component 6 (MCM-6) is one of the six proteins of the MCM family, which are involved in the initiation of DNA replication, represents a marker of proliferating cells. The goal of this study was to evaluate the prognostic relevance of the neoplastic cell proliferation rate in patients with Hodgkin's lymphoma (HL). We evaluated the formalin-fixed paraffin-embedded lymph node biopsy specimens from 55 patients by using monoclonal antibody against MCM-6 and compared these findings with clinical data and treatment outcome. Median of MCM-6 expression was 85% (range: 35%-99%). In multivariate analysis, MCM-6 expression, B symptoms, and age were not statistically significant predictor for relapse in contrary to response (P=.001) and stage of disease (P=.048). Patients with lower MCM-6 expression rates showed higher relapse rate and lower disease-free survival (DFS). Meanwhile, patients with MCM-6 expression less than 85% showed shorter DFS (P=.031). We hypothesize that in group of patients with lower MCM-6 expression rate, a larger proportion of proliferating malignant cells are arrested in the very early phase of mitosis, in comparison to the group of patients with higher MCM-6 expression, and this could imply a shorter and probably higher relapse rate in the former group.

Published
2017

2. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma

Author

Sebastien Labonte, Wedad Hanna, and Bizhan Bandarchi-Chamkhaleh

Subjects
Pathology, medicine.medical_specialty, Skin Neoplasms, Histology, CD34, Antigens, CD34, Dermatology, Dermatofibroma, Pathology and Forensic Medicine, Adjuvant therapy, medicine, Dermatofibrosarcoma protuberans, Humans, Histiocytoma, Benign Fibrous, biology, business.industry, CD117, Dermatofibrosarcoma, Imatinib, medicine.disease, Immunohistochemistry, digestive system diseases, Proto-Oncogene Proteins c-kit, biology.protein, Sarcoma, Fibroma, business, medicine.drug
Abstract

Background: Dermatofibrosarcoma protuberans (DFSP) is a relatively uncommon spindle cell tumor of the skin. It is locally aggressive and can be a therapeutic challenge. There are case reports of partial response of DFSP to the tyrosine kinase inhibitor STI571 (Imatinib), despite the reported negativity of the tumor cells for CD117. At least one publication reported focal CD117 positivity of DFSP cells, and we would like to clarify the issue. Cellular dermatofibroma (CDF) can mimic DFSP, but typical cases are easily differentiated from DFSP by their staining pattern for CD34 and factor 13a. We also report our experience with CD117 staining of typical CDFs. Methods: Thirty-seven cases of clear-cut DFSP and 13 cases of clear-cut CDF were retrieved from the archives of Sunnybrook Health Sciences Center between 2000 and 2005. Results: All DFSPs were CD34 (+), factor 13a (−) and CD117 (−). All CDFs were factor 13a (+), CD34 (−) and CD117 (−). Conclusions: Our study on a relatively large number of cases confirms the negativity of DFSP and CDF for CD117. Therefore, if adjuvant therapy is attempted with drugs such as STI571 (Imatinib), the eligibility of patients should not be based on immunohistochemical assessment of CD117 expression.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results